A

Acer Therapeutics Inc
F:P6NA

Watchlist Manager
Acer Therapeutics Inc
F:P6NA
Watchlist
Price: 0.804 EUR Market Closed
Market Cap: 28.8m EUR

Relative Value

There is not enough data to reliably calculate the relative value of P6NA.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

P6NA Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
Forward
3.8
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.3
Industry
21.4
Forward
-1.9
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1.1
Industry
16.4
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.2
Industry
22.8
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1
Industry
2.2
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.9
Forward
3.8
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.5
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.4
Industry
13
vs History
vs Industry
Median 3Y
-1.3
Median 5Y
-1.4
Industry
16.5
Forward
-2.2
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1
Industry
15.6
vs History
vs Industry
Median 3Y
-1
Median 5Y
-1
Industry
18.7
vs History
vs Industry
Median 3Y
4.2
Median 5Y
4.3
Industry
1.9

Multiples Across Competitors

P6NA Competitors Multiples
Acer Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Acer Therapeutics Inc
F:P6NA
28.8m EUR 0 -1.3 -1.4 -1.3
US
Eli Lilly and Co
NYSE:LLY
978.2B USD 16.5 53.1 35.7 38.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.6B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
257.9B CHF 4.2 27.4 11.7 13.6
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP 4.8 29.6 108.2 158.3
US
Merck & Co Inc
NYSE:MRK
265B USD 4.1 13.9 9.9 11.7
CH
Novartis AG
SIX:NOVN
207.5B CHF 4.7 18.2 11.6 14.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK 4.8 14.7 10.3 12
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
142.7B USD 2.3 14.5 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
A
Acer Therapeutics Inc
F:P6NA
Average P/E: 23.9
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.1
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.4
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.6
37%
0.8
US
Merck & Co Inc
NYSE:MRK
13.9
15%
0.9
CH
Novartis AG
SIX:NOVN
18.2
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
14.7
3%
4.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.5
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
A
Acer Therapeutics Inc
F:P6NA
Average EV/EBITDA: 439.5
Negative Multiple: -1.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
34%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.7
5%
2.3
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
US
Merck & Co Inc
NYSE:MRK
9.9
6%
1.6
CH
Novartis AG
SIX:NOVN
11.6
6%
1.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
A
Acer Therapeutics Inc
F:P6NA
Average EV/EBIT: 1 883.1
Negative Multiple: -1.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.2
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.6
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.3
23%
6.9
US
Merck & Co Inc
NYSE:MRK
11.7
8%
1.5
CH
Novartis AG
SIX:NOVN
14.9
12%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
12
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4